Mizuho dropped their price target on Sage Therapeutics from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th.
Piper Sandler restated an “overweight” rating and set a $26.00 price target (down from $52.00) on shares of Sage Therapeutics in a research report on Wednesday.
Get Sage Therapeutics alerts:Get Our Latest Stock Analysis on SAGEInstitutional Inflows and OutflowsSage Therapeutics Stock PerformanceSeveral hedge funds have recently modified their holdings of SAGE.
As a group, equities analysts predict that Sage Therapeutics will post -6.43 EPS for the current year.
Featured StoriesReceive News &amp; Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Analysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $13.76